Full Program
Program

BREAK

FORUM

INVITED SYMPOSIUM

MEET THE PROFESSOR

ON-DEMAND ORAL

OTHER EVENT

PLENARY LECTURE

PRODUCT THEATER

SPONSORED SYMPOSIUM

SYMPOSIUM

Tuesday, 17 March, 2026
Time Hall A1 Hall A2 Auditorium 10+11 Hall A3 Auditorium 15 Auditorium 12 Hall 180-181 Exhibition On-Demand Virtual Gallery
07:00-20:00
ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:30-10:30
BALANCING THE AD’S EQUATION: TAU, PROTEOSTASIS, AND VULNERABLE NETWORKS
GENETIC RISK AND MOLECULAR MECHANISMS IN AD
PROTEOMICS, LIPIDOMICS & RELATED MECHANISMS
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
INTEGRATING SLEEP, EEG, AND DIGITAL BIOMARKERS IN NEURODEGENERATION
ADVANCING PRECISION BIOMARKERS ACROSS THE NEURODEGENERATIVE CONTINUUM
09:30-10:30
INDUSTRY SYMPOSIUM 01 (NO CME/CPD CREDIT)
10:30-11:00
COFFEE BREAK
10:30-11:00
11:00-13:00
INDUSTRY SYMPOSIUM 02 (NO CME/CPD CREDIT)
PREVENTION AND RESILIENCE IN DEMENTIA AND AGING
α-SYNUCLEINOPATHIES MECHANISMS, PATHOPHYSIOLOGY: MODELING OF DISEASE PROGRESSION
FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
CHOLINERGIC MECHANISMS & TREATMENTS IN AD SPECTRUM
MOLECULAR DRIVERS OF NEURODEGENERATIVE DISORDERS
13:00-14:00
LUNCH BREAK
13:00-14:00
14:00-15:00
INDUSTRY SYMPOSIUM 03 (NO CME/CPD CREDIT)
14:00-15:30
BIOMARKERS AND NETWORKS OF RESILIENCE TO AD
IMMUNE–METABOLIC NETWORKS DRIVING TAU PATHOLOGY AND NEURODEGENERATION
INVITED SYMPOSIUM (NONE CME/CPD CREDIT) BY INVITATION ONLY
BIOMARKERS OF SYNAPTIC LOSS, TAU PROGRESSION, AND EARLY NETWORK DYSFUNCTION IN AD
GENOMIC AND MULTI-OMIC INSIGHTS IN AD, PD, AND RELATED DISORDERS
14:00-15:45
THE APP PATHWAY: FROM HIDDEN FRAGMENTS TO THERAPEUTIC TARGETS IN AD
15:30-15:45
SHORT BREAK
15:30-15:45
15:45-16:45
PLENARY LECTURE 01, 02
16:45-17:00
SHORT BREAK
16:45-17:00
17:00-18:00
FIRESIDE DEBATE: INDUSTRY MEETS ACADEMIA: MOONSHOTS AND MILESTONES: IS THE FUTURE OF NEURODEGENERATION DRUG DISCOVERY IN STARTUPS, FOUNDATIONS, BIG PHARMA, OR ACADEMIA
18:05-18:47
ADPDTM CEREMONY AND AWARDS
18:57-20:00
WELCOME RECEPTION IN EXHIBITION
Wednesday, 18 March, 2026
Time Hall A1 Hall A2 Auditorium 10+11 Hall A3 Auditorium 15 Auditorium 12 Hall 180-181 Exhibition/Product Theater Exhibition On-Demand Virtual Gallery
07:00-08:30
ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:00-08:30
PLENARY LECTURE 03: DON PRICE MEMORIAL LECTURE
08:30-08:40
BREAK
08:30-08:40
08:40-10:40
INDUSTRY SYMPOSIUM 04 (NO CME/CPD CREDIT)
MICROGLIA/ASTROGLIA FROM MECHANISMS TO POTENTIAL TREATMENTS
ALPHA-SYNUCLEIN, AGGREGATION, MISFOLDING, PATHOGENESIS AND TRANSLATIONAL ASPECTS
DECODING APOE: GENETICS, LIPIDS, AND DISEASE
TRANSLATIONAL DRUG DISCOVERY AND MODELS
WHITE MATTER SIGNATURES IN NEURODEGENERATION AND PROGNOSIS
MECHANISTIC BIOMARKERS DEFINING PROGRESSION IN AD, PD, AND LBD
10:40-11:10
EXHIBITION, POSTERS AND COFFEE BREAK
10:40-11:10
PRODUCT THEATER 01 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
11:10-12:50
INDUSTRY SYMPOSIUM 05 (NO CME/CPD CREDIT)
12:50-14:30
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
12:50-14:30
13:00-14:00
MEET THE PROFESSOR - TICKETED EVENT
13:00-13:30
PRODUCT THEATER 02 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
14:30-15:30
FORUM 01: BIOMARKERS TO BENEFIT: ACCELERATING TRANSLATION OF MULTI-MODAL BIOMARKERS INTO DISEASE-MODIFYING THERAPIES
14:30-16:30
DECODING THE AMYLOID–TAU AXIS IN AD
MITOCHONDRIAL PATHWAYS IN NEURODEGENERATION AND THERAPY
PREDICTING PD & LBD: BIOMARKERS AND BEYOND
REWIRING NEUROINFLAMMATION: MICROGLIA AND IMMUNE THERAPEUTICS
GENOMIC LANDSCAPES IN AD, PD, AND DEMENTIA
MODULATING NEUROINFLAMMATION, Α-SYNUCLEIN, LRRK2, AND DOPAMINERGIC REPAIR: EARLY HUMAN DATA
15:35-16:35
FORUM 02: BEYOND ONE SIZE FITS ALL: PRECISION DRUG DEVELOPMENT, AI METHODS, AND TRIAL DESIGN IN AD/PD
16:30-17:00
EXHIBITION, POSTERS AND COFFEE BREAK
16:30-17:00
PRODUCT THEATER 03 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
17:00-19:00
INDUSTRY SYMPOSIUM 06 (NO CME/CPD CREDIT)
FLUID BIOMARKERS AND MULTIMODAL IMAGING: DIAGNOSIS, PROGNOSIS AND DISEASE PROGRESSION
GENETIC LANDSCAPES OF ALZHEIMER’S AND PARKINSON’S
FROM RISK TO RESILIENCE IN COGNITIVE DECLINE
FUNCTIONAL AND STRUCTURAL IMAGING IN NEURODEGENERATION
CAA AND BBB DYSFUNCTION: DIAGNOSIS, RISK FACTORS AND CELLULAR CHANGES
Thursday, 19 March, 2026
Time Hall A1 Hall A2 Auditorium 10+11 Hall A3 Auditorium 15 Auditorium 12 Hall 180-181 Exhibition/Product Theater Exhibition On-Demand Virtual Gallery
07:00-08:30
ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:00-08:30
PLENARY LECTURE 04
08:30-08:40
BREAK
08:30-08:40
08:40-10:40
INDUSTRY SYMPOSIUM 07 (NO CME/CPD CREDIT)
MECHANISMS AND THERAPEUTICS IN THE ALS–FTD SPECTRUM (SOD-1, TDP-43, C9ORF72 AND TMEM106B)
MECHANISTIC INSIGHTS INTO PD AND LBD PATHOLOGY
MECHANISTIC INSIGHTS INTO SEX DIFFERENCES IN NEURODEGENERATION
PERIPHERAL AND CENTRAL IMMUNITY ACROSS AD/PD
LIPIDS, APOE IN AD, PD & MS
10:40-11:10
EXHIBITION, POSTERS AND COFFEE BREAK
10:40-11:10
PRODUCT THEATER 04 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
11:10-12:50
SYMPOSIUM
12:50-13:50
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
12:50-13:50
13:00-13:30
PRODUCT THEATER 05 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
13:00-14:00
MEET THE PROFESSOR - TICKETED EVENT
13:50-15:50
INDUSTRY SYMPOSIUM 08 (NO CME/CPD CREDIT)
INFLAMMATION, LIPIDS, AND GLIAL PATHWAYS IN DEMENTIA
GENETIC AND CELLULAR PATHWAYS - FROM LRRK2 TO LBD AND PD
AI AND DIGITAL TOOLS FOR AD/PD CARE
DECODING TAU AND ITS CELLULAR PARTNERS IN DISEASE
MULTIMODAL MECHANISMS DRIVING EARLY AD PROGRESSION
15:50-16:20
EXHIBITION, POSTERS AND COFFEE BREAK
15:50-16:20
PRODUCT THEATER 06 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
16:20-17:20
INDUSTRY SYMPOSIUM 09 (NO CME/CPD CREDIT)
16:20-18:20
ARIA AND CAA: MECHANISMS
LINKING PATHOLOGY AND BIOMARKERS ACROSS NEURODEGENERATIVE DISORDERS
PET AND MULTIMODAL IMAGING IN AD, PD, AND LBD
GUT–BRAIN AXIS IN AD AND PD
FLUID BIOMARKERS AND MULTIMODAL IMAGING
BIOMARKER PATHWAYS LINKING AMYLOID, TAU, AND NEURODEGENERATION
17:30-18:30
FORUM 03: REWIRING COGNITION: TARGETING CHOLINERGIC, SYNAPTIC, AND NETWORK-BASED MECHANISMS IN AD, PD, AND LBD
Friday, 20 March, 2026
Time Hall A1 Hall A2 Auditorium 10+11 Hall A3 Auditorium 15 Auditorium 12 Hall 180-181 Exhibition/Product Theater Exhibition On-Demand Virtual Gallery
07:00-08:30
ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:00-08:30
PLENARY LECTURE 05
08:30-08:40
BREAK
08:30-08:40
08:40-10:40
INDUSTRY SYMPOSIUM 10 (NO CME/CPD CREDIT)
CHOLINERGIC PATHWAYS: FROM MECHANISMS TO TREATMENTS
SYNAPTIC DYSFUNCTION AND BIOMARKERS IN AD/PD
APOE 4 DISTICT SIGNATURE IN AD AND PD
PROTEIN AGGREGATES, NEUROGENESIS, AND TRANSLATIONAL OPPORTUNITIES
GENETICS, APOE AND LIPID PATHWAYS IN AD
10:40-11:10
EXHIBITION, POSTERS AND COFFEE BREAK
10:40-11:10
PRODUCT THEATER 07 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
11:10-12:50
INDUSTRY SYMPOSIUM 11 (NO CME/CPD CREDIT)
12:50-13:50
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
12:50-13:50
13:00-14:00
MEET THE PROFESSOR - TICKETED EVENT
13:00-13:30
PRODUCT THEATER 08 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
13:50-15:50
ABETA TARGETING THERAPIES IN AD: PROGRESS AND PERSPECTIVES
GENETIC INSIGHTS IN AD, PD AND PSYCHIATRIC DISORDERS
CEREBROVASCULAR CHANGES, CAA, BBB
INDUSTRY SYMPOSIUM 12 (NO CME/CPD CREDIT)
FLUID BIOMARKERS AND IMAGING - LINKING MECHANISMS TO CARE
MECHANISMS AND PATHWAYS TO THERAPY IN AD, FTD, AND ALS
15:50-16:20
EXHIBITION, POSTERS AND COFFEE BREAK
15:50-16:20
PRODUCT THEATER 09 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
16:20-17:20
INDUSTRY SYMPOSIUM 13 (NO CME/CPD CREDIT)
16:20-18:20
TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS
PET, MULTIMODAL IMAGING AND BIOMARKERS IN CLINICAL USE ACROSS DEMENTIAS
ARIA AND CAA: BIOMARKERS
LYSOSOMAL STORAGE DISEASES AND ENDOLYSOSOMAL PROTEOSTASIS MECHANISMS
REAL-WORLD OUTCOMES AND MECHANISTIC INSIGHTS IN ANTI-AMYLOID TREATMENT
INTEGRATED BIOMARKERS FOR EARLY DETECTION AND MECHANISTIC STRATIFICATION
17:30-18:30
FORUM 04: TARGETS TO THERAPIES: TRANSLATIONAL R&D FOR Α-SYNUCLEIN, LRRK2, AND GBA PATHOLOGIES IN PD, LBD, AND MSA
18:30-18:40
SHORT BREAK
18:30-18:40
18:40-19:40
INDUSTRY SYMPOSIUM 14 (NO CME/CPD CREDIT)
COGNITIVELY HEALTHY CENTENARIANS: HOW DO THEY DO IT?
AD: GENETIC RISK AND BEYOND
AI, GENOTYPING, AND DIGITAL TOOLS IN NEURODEGENERATION
MODELING NEURODEGENERATIVE DISEASE IN PRIMATES
PSP IN FOCUS: MECHANISMS, MEASURES, AND MEDICINES
Saturday, 21 March, 2026
Time Hall A1 Hall A2 Auditorium 10+11 Hall A3 Auditorium 15 Auditorium 12 Hall 180-181 Exhibition/Product Theater Exhibition On-Demand Virtual Gallery
07:00-08:30
ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:00-08:30
PLENARY LECTURE 06
08:30-08:40
BREAK
08:30-08:40
08:40-10:40
INDUSTRY SYMPOSIUM 15 (NO CME/CPD CREDIT)
ANTI-AMYLOID IMMUNOTHERAPY: MECHANISMS AND PRACTICE
TAU BIOLOGY AND THERAPEUTIC STRATEGIES
GLP-1 MECHANISMS AND THERAPEUTICS IN NEURODEGENERATION
RESTORING NEURAL RESILIENCE IN ALS AND ALZHEIMER’S DISEASE
NEXT-GENERATION BIOMARKERS ACROSS AD, PD, AND LBD
PATHWAYS TO NEURODEGENERATION: SYNAPSES, INFLAMMATION, AND PROTEINOPATHY
10:40-11:10
EXHIBITION, POSTERS AND COFFEE BREAK
10:40-11:10
PRODUCT THEATER 10 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
11:10-13:10
INDUSTRY SYMPOSIUM 16 (NO CME/CPD CREDIT)
ANTIBODIES & SHUTTLES FOR TARGETED BRAIN DELIVERY
PD AND LEWY BODY DISORDERS: FROM PREVENTION TO NOVEL THERAPIES
MICROGLIA AND NEUROIMMUNE TARGETS IN AD, FTD AND PD
BIOMARKER SIGNATURES IN PRECLINICAL AD AND NEURODEGENERATIVE DISEASES
TARGETING TAU: MECHANISMS AND THERAPIES
MECHANISTIC MODIFIERS OF AD: APOE, IMMUNITY, AND NEURAL CIRCUITS
13:10-14:10
EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
13:10-14:10
MEET THE PROFESSOR - TICKETED EVENT
14:10-16:10
ADVANCES IN AD TREATMENT
EMERGING THERAPIES ACROSS AD, PD, LBD
TRANSLATIONAL TREATMENT STRATEGIES IN AD & FTD; NEW TARGETS
FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD, HD
MOLECULAR SIGNATURES AND CONFORMATIONAL STATES IN AD AND LBD
MOLECULAR NEUROINFLAMMATION PATHWAYS
14:10-15:10
INDUSTRY SYMPOSIUM 17 (NO CME/CPD CREDIT)
15:30-16:30
FORUM 05: IMMUNOTHERAPY 2.0: REDEFINING MICROGLIAL, TREM2, AND ADAPTIVE IMMUNE ENGAGEMENT IN AD AND PD
16:30-17:00
EXHIBITION, POSTERS AND COFFEE BREAK
16:30-17:00
17:00-19:05
TAU, AMYLOID, AND SYNUCLEIN: MECHANISMS AND TREATMENTS
INTEGRATING IMAGING AND BIOMARKERS IN AD, PD, AND LBD
PROTECTIVE AND PATHOLOGICAL PATHWAYS IN COGNITIVE DECLINE
MOLECULAR MECHANISMS AND EMERGING THERAPIES IN PD, MSA AND LBD
TRACKING PD, GBA-PD AND MSA BIOMARKERS, MECHANISMS, AND PROGRESSION
18:05-19:05
FORUM 06: BEYOND AMYLOID AND TAU: EMERGING TARGETS AND MULTI-PATHWAY APPROACHES IN NEURODEGENERATION AND NEUROINFLAMMATION – PROMISE AND PITFALLS
19:05-19:15
CLOSING SESSION